07:00 , May 31, 2010 |  BioCentury  |  Finance

Performance Counts

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond. While in total these private and public biotechs also have registered the...
07:00 , Aug 2, 2004 |  BC Week In Review  |  Company News

Inflazyme autoimmune, inflammation news

IZP restructured its R&D efforts to focus on its Complement Inhibition and Prodaptin technologies. The company will reduce its headcount by 42, or about half, to 40. Positions will be cut across the combined operations...
07:00 , Apr 26, 2004 |  BC Week In Review  |  Company News

AdProTech, Inflazyme deal

IZP completed its previously announced acquisition of Adprotech for 12.7 million shares, valued at C$18.4 million (US$13.7 million) using IZP's pre-deal closing price of C$1.45 on April 20. The deal was announced earlier this month...
07:00 , Apr 12, 2004 |  BC Week In Review  |  Company News

AdProTech, Inflazyme, Avant deal

IZP will acquire Adprotech in a stock deal worth about C$20 million (US$15.2 million). IZP will issue 12.7 million shares at about C$1.59, based on IZP's 15-day closing average prior to the deal. The deal...
07:00 , Apr 8, 2004 |  BC Extra  |  Company News

Inflazyme acquiring Adprotech

Inflazyme (TSE:IZP) said it will acquire Adprotech (Cambridge, U.K.) in a stock deal worth about C$20 million ($15.2 million). IZP will issue 12.7 million shares at about C$1.59, based on the 15-day closing average of...
07:00 , Aug 4, 2003 |  BioCentury  |  Strategy

Clinical leaders

Clinical leaders Company Status Country Alizyme (LSE:AZM) Ph III U.K. Antisoma (LSE:ASM) Ph III U.K. Ark Therapeutics Ph III U.K. Basilea Ph...
07:00 , Jun 30, 2003 |  BC Week In Review  |  Clinical News

APT070 genetically modified fragment of anti-CD35 antibody regulatory update

The FDA granted Orphan Drug designation to Adprotech's APT070 to prevent delayed graft function in solid organ transplantation. The product received Orphan Medicinal Product designation from the EU to prevent post transplantation graft dysfunction in...
07:00 , May 19, 2003 |  BioCentury  |  Product Development

RA rally

RA rally Company Compound Description Status Partner Notes Abbott Humira adalimumab Anti-TNF Mkt Cambridge Antibody Ph II for psoriasis Amgen Enbrel etanercept Anti-TNF Mkt Wyeth Ph III for psoriasis Amgen Kineret anakinra IL-1...
07:00 , May 12, 2003 |  BioCentury  |  Finance

Europe's top decile & quartile

Europe's top decile & quartile Company Aggregate raised (2000-1Q03) PharmaMar $173.3 Biovitrum $85.0 Cellzome $71.3 Strakan Group $65.7 Cytos $59.1 ProSkelia $58.4 RiboTargets $55.6 Micromet ...
08:00 , Mar 3, 2003 |  BC Week In Review  |  Clinical News

APT070: Phase IIa

Adprotech started a dose-escalating, double-blind, placebo-controlled, U.K. Phase IIa study in 45 transplant patients. APT070 also is in Phase II testing for rheumatoid arthritis. Adprotech Ltd., Cambridge, U.K.   Product: APT070   Business: Autoimmune/Inflammation   Molecular target: ...